<DOC>
	<DOCNO>NCT00446303</DOCNO>
	<brief_summary>A phase II multicentre trial maintenance Azacitidine MDS patient achieve complete partial remission ( CR PR ) intensive chemoterapy . The primary objective response duration ( MDS AML )</brief_summary>
	<brief_title>A Phase II Study Maintenance With Azacitidine MDS Patients</brief_title>
	<detailed_description>A academic multicentre study whose aim study benefit maintenance therapy 24 monthly course af azacytidine high-risk MDS patient , previously treat intensive chemotherapy obtention partial complete response eligible allogeneic transplantation</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>MDS int 2 high IPSS score eitherRAEB 1 2 accord WHO classification ( see appendix 1 ) CMML WBC &lt; 13 109/l RAEBT accord FAB classification ( see appendix 1 ) without ( 8 ; 21 ) , inv 16 ( 16 ; 16 ) AML secondary MDS ( sAML ) confirm MDS phase least 2 month available bone marrow cytogenetics diagnosis AML AND CR PR accord IWG criterion ( see appendix 3 ) one two course predefined intensive chemotherapy ( see page 12 ) available cytogenetics evaluation response Aged 18 year age Written Informed consent Adequate Contraception , relevant Negative pregnancy test relevant . Patients eligible azacitidine confirmatory trial ( azacitidine `` versus `` conventional treatment `` ) unwilling participate AML secondary myeloproliferative MDS/MPD WHO subgroups except CMML WBC &lt; 13 109/l Therapy relate MDS ( chemo radiotherapy previous neoplasm immune disorder ) Patients eligible allogeneic bone marrow transplantation ( identify donor ) Liver and/or kidney failure prohibit use azacitidine . Creatininemia &gt; 1.5 normal value ALAT ASAT &gt; 3N Bilirubin &gt; 2 N , unless due dyserythropoiesis Known hypersensitivity azacitidine mannitol Other tumor , unstable last three year , except situ uterine carcinoma basal skin tumor Uncontrolled infection , WHO Performance status &gt; 2 Life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>AML</keyword>
	<keyword>Intensive chemotherapy</keyword>
	<keyword>azacitidine</keyword>
</DOC>